Could Aduhelm be pulled? Will Incyte get acquired? Here are some of your wildest New Year predictions.
Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.
Lilly's remarkable decision to run a head-to-head trial of donanemab versus Aduhelm spells another big readout for the amyloid targeting space.
Black box warnings could limit the sales of their newly approved therapeutics.
Despite industry outcry, new data question how relevant the rule would have been anyway.